TY - JOUR
T1 - A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies
AU - Perani, Daniela
AU - Iaccarino, Leonardo
AU - Lammertsma, Adriaan A.
AU - Windhorst, Albert D.
AU - Edison, Paul
AU - Boellaard, Ronald
AU - Hansson, Oskar
AU - Nordberg, Agneta
AU - Jacobs, Andreas H.
AU - IMBI Project
AU - Bottlaender, Michel
AU - Brooks, David
AU - Carroll, Michael A.
AU - Chalon, Sylvie
AU - Gee, Anthony
AU - Gerhard, Alexander
AU - Halldin, Christer
AU - Herholz, Karl
AU - Herth, Matthias M.
AU - Hinz, Rainer
AU - Knudsen, Gitte M.
AU - Kuhnast, Bertrand
AU - López-Picón, Francisco
AU - Moresco, Rosa Maria
AU - Pappata, Sabina
AU - Rinne, Juha O.
AU - Rodriguez-Vieitez, Elena
AU - Santiago-Ribeiro, Marie Joao
AU - Turkheimer, Federico E.
AU - van Laere, Koen
AU - Varrone, Andrea
AU - Vercouillie, Johnny
AU - Winkeler, Alexandra
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications.
AB - Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications.
KW - Amyloid
KW - Neuroinflammation
KW - PET molecular imaging
KW - Protheinopathies
KW - Radiotracers
KW - Tau
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067487439&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31230910
U2 - https://doi.org/10.1016/j.jalz.2019.02.004
DO - https://doi.org/10.1016/j.jalz.2019.02.004
M3 - Article
C2 - 31230910
SN - 1552-5260
VL - 15
SP - 1081
EP - 1103
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 8
ER -